Y-mAbs Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-04-01
- Employees
- 100
- Market Cap
- $676.1M
- Website
- http://www.ymabs.com
- Introduction
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in Ne...
Brain Tumor Therapeutics Market Forecast 2025-2030: A $5.28
The Brain Tumor Therapeutics Market is projected to grow from USD 3.28 billion in 2024 to USD 5.28 billion by 2030, driven by advances in healthcare technologies and increased investment in oncology research. Key areas explored include market penetration, development, diversification, competitive assessment, and product innovation. Challenges include high R&D costs and regulatory hurdles. Opportunities lie in personalized medicine and novel drug delivery systems.
Michael Wernke is Fighting Corporate Malfeasance – and Winning Big for Investors
Pomerantz partner Michael Wernke led high-profile securities fraud cases against Teva Pharmaceuticals, Y-mAbs Therapeutics, and Nikola Corp., securing favorable settlements and refining legal strategies for future cases.
© Copyright 2024. All Rights Reserved by MedPath